Zhongke Borui Secures Tens of Millions in Series A Strategic Financing to Advance Cerebrovascular Disease Solutions

VCBeat learned第一时间 that recently, Casibrain (Beijing) Technology Co., Ltd. (hereinafter referred to as "Casibrain Technology") announced the completion of a multi-million yuan A-round strategic financing.This round of financing was exclusively invested by Beijing Aeonmed Co., Ltd. ("Aeonmed" for short).The funds raised from this round of financing will be mainly used to accelerate the clinical trial process of multiple product lines, innovative product research and development, as well as marketing and sales efforts.

Regarding this round of financing, Zhang Xin, founder of Casibrain Technology, stated："We are very grateful to Beijing Aeonmed Co., Ltd. for recognizing Casibrain Technology. Beijing Aeonmed Co., Ltd. is a leading enterprise in the research, development, and manufacturing of anesthesia and respiratory medical devices in China, with products covering six major business sectors: respiratory and ICU, anesthesia and operating rooms, emergency and disaster response, laminar flow and hospital engineering, sleep and respiratory diseases, and IVD. Not only are Aeonmed's products innovative, but they have also almost penetrated every channel. Moving forward, Casibrain Technology will leverage Aeonmed’s distribution and promotion channels to achieve comprehensive product coverage from point to surface. In terms of product development, in addition to the innovative products already developed, Casibrain Technology will continue to focus on three key areas—'brain function monitoring,' 'brain function imaging,' and 'brain function treatment'—to expand its innovative medical device portfolio. Throughout this process, we hope to collaborate with more clinical experts, transforming brain science technology into innovative medical devices tailored to meet the needs of various clinical scenarios, serving the diagnosis and treatment of cerebrovascular disease patients."

Casibrain Technology was incubated at the Institute of Automation, Chinese Academy of Sciences. Researcher Tianzi Jiang, Director of the Brainnetome Center at the Institute of Automation, Chinese Academy of Sciences, and Foreign Member of the European Academy of Sciences, serves as the Chief Scientist. Researcher Xin Zhang, Key Technical Talent of the Chinese Academy of Sciences and High-Level Leading Talent of Zhongguancun, serves as the Chairman and General Manager. Under the guidance of Researcher Tianzi Jiang, the Brainnetome Center, where the team is located, has accumulated over 20 years of experience in the field of brain science and proposedBrand-new important achievements in brain science, such as the human brain network atlas and photoelectric synchronous brain activity detector, provided strong support for Casibrain Technology to develop a comprehensive solution for brain science.

Focusing on cerebrovascular diseases, a major category of neurological disorders, Casibrain Technology continues to deepen its research and accelerate the transformation of the National Key Scientific Instrument Development Project supported by the Ministry of Science and Technology — the photoelectric synchronous brain activity imager. This has led to the creation of the world's first integrated multimodal brain function imaging system that combines electroencephalography (EEG) with functional near-infrared spectroscopy (fNIRS). Through brain-computer interface technology, it assists in evaluating the treatment effectiveness for rehabilitation patients.

Currently, Casibrain Technology has applied for and been granted more than 50 intellectual property rights. It has formed product directions such as "brain physiology," "brain consciousness," and "brain function," and launched solutions covering precision diagnosis and treatment of brain functional diseases and brain-computer feedback rehabilitation.Non-invasive cerebral oxygen monitor, Non-invasive whole-brain oxygen monitor, Photoelectric synchronous multimodal brain imaging instrument, Intelligent brain diagnosis and treatment and research platformA series of innovative devices, transforming cutting-edge neuroscience technology achievements through engineering and industrialization into medical device products for clinical use.

Casibrain Technology Brain Diagnosis and Treatment Innovation Device Matrix

Currently, the company is still actively expanding more clinical application scenarios. In addition to developing innovative products such as non-invasive full-brain multi-channel oxygen monitors to achieve precise monitoring of all brain regions in stroke patients, the company also fully utilizes the advantages of the Institute of Automation, Chinese Academy of Sciences, in the field of artificial intelligence. By organically combining brain science technology with artificial intelligence technology, it assists brain function devices in achieving accurate diagnosis and treatment of brain functions, builds a matrix of innovative brain devices, and creates an intelligent brain diagnosis and treatment platform.

Thanks to the company's innovative R&D capabilities in the field of brain science, Casibrain Technology has been approved as"National High-tech Enterprise" "Zhongguancun High-tech Enterprise"" andBeijing "Specialized, Precise, Unique, and Innovative" Small and Medium-sized Enterprises, and becomeBeijing's First Batch of "Specialized, Refined, Unique, and Innovative" Enterprises, continuously promoting the production, registration, and sales of medical devices that transform cutting-edge brain science technologies from the Chinese Academy of Sciences, with a focus on the research and development of high-quality brain diagnosis and treatment equipment.

In terms of brain oxygen monitoring layout in 2021, the non-invasive regional cerebral oxygen saturation monitor independently developed by Casibrain Technology hasObtained multiple registrations, including NMPA certification and CE certification.。In the process of collaborating with industry partners related to anesthesiology and intensive care units, the company has gradually formed cooperative models such as modularization, promoting the widespread application of cerebral oxygen monitoring technology in clinical fields, achieving distribution coverage from point to surface, and successfully implementing it in major benchmark hospitals across China.Currently, it has been promoted and covered more than 200 hospitals.. Not only that, but the company is also committed toInnovative brain oxygen detection products have been exported to Europe, America, and countries along the "Belt and Road". Among them, more than ten medical institutions in Europe have already implemented the technology.

The weight of brain tissue accounts for about 2% of the total body weight, while its oxygen consumption accounts for approximately 20% of the body's total oxygen consumption. If the brain is deprived of oxygen for 10 seconds, a person will lose consciousness, and deprivation for 4-6 minutes may lead to brain death. More critically, the higher nervous system near the cerebral cortex has an even shorter tolerance time for hypoxia and ischemia, making it more difficult to monitor. A large amount of clinical data has shown that the incidence of cerebral ischemia and hypoxia during surgery remains persistently high. Notably, the rate of cerebral hypoxia during aortic arch surgery alone can be as high as 73%.

Although continuous monitoring of brain tissue oxygen saturation (also known as cerebral oxygen saturation) is crucial, in the past, clinical detection of cerebral oxygen saturation was often performed by placing catheters in the carotid artery and jugular vein to intermittently collect intracranial blood samples. These samples were then analyzed using a blood gas analyzer. Due to significant environmental constraints during monitoring, it was difficult to use this method for real-time cerebral oxygen monitoring.

Near-infrared spectroscopy effectively solves this problem. This method can accurately calculate cerebral oxygen saturation by measuring the different absorption of near-infrared light by oxygenated hemoglobin and deoxygenated hemoglobin in brain tissue, thereby enabling non-invasive, real-time, and precise monitoring of local brain tissue oxygenation. However, there are two major challenges to truly achieving non-invasive real-time monitoring: overcoming the influence of the skull and selecting optical signals related to cerebral oxygenation signals to avoid the impact of skin color on the optical signals.

Casibrain TechnologyCasibrain (Beijing) Technology Co., Ltd. has developed the world's first non-invasive cerebral oxygen monitor that integrates both wired and wireless functions.The system features wireless, non-invasive, and multi-channel capabilities, which can assist clinical practices in achieving non-invasive continuous monitoring of blood oxygen saturation in the brain, body tissues, and extremities, allowing for the early detection of hypoxia and ischemia in the brain and limbs. Additionally, the product is supported by dedicated software for big data analysis, which can help clinical experts with data review and big data analysis.

Building on existing technological advancements, enterprises have made further progress. Targeting stroke centers, they have collaborated with the team led by Professor Ji Xunming, Vice President of Capital Medical University and academician of the Chinese Academy of Engineering, to achieve results involving brain tissues such as the frontal lobe, parietal lobe, temporal lobe, and occipital lobe.Eight Deep Brain RegionsNon-invasive, continuous, accurate, real-time monitoring, developed an innovative medical device——Non-invasive Whole Brain Oxygen Monitor, and in November 2022, the project received special support from the National Key Research and Development Program of the Ministry of Science and Technology. In December 2023, it was approved by the National Medical Products Administration as"Innovative Medical Devices", completedFrom Single Brain Area to Whole Brain Multiple Areas MonitoringThe breakthrough. With this product, the application scope of Casibrain Technology will be further expanded. In addition to the departments of anesthesiology and intensive care, it can also be practically applied in scenarios such as stroke centers.

One of the core technologies of this device lies in the construction of a full-brain multi-layered hierarchical tissue model. Based on a large amount of magnetic resonance imaging (MRI) data from the Brainnetome Center at the Institute of Automation, Chinese Academy of Sciences, parameters such as skull thickness, density, and optical transmittance of various brain regions were set to build an accurate optical and structural head tissue model. This enabled optical simulation experiments for different brain regions, providing a foundation for subsequent algorithm development as well as the collection and reception of optical signals.

One of the core technologies of this device lies in the development of an enhanced probe technology. This technology utilizes a light-guiding structure, along with components such as lenses and light-guiding rods, as well as a planned optical path, enabling light to be transmitted and received along extremely fine pathways. It addresses issues of interference from hair, skin tone, and other factors that typically affect optical methods, allowing effective monitoring of brain areas covered by hair. Additionally, the device features synchronous monitoring capabilities, ensuring the synchronized transmission and reception of eight optical signals, avoiding data delays and inconsistencies, thereby enhancing the accuracy and real-time performance of the monitoring.

Beijing Aeonmed Co., Ltd. is a leading enterprise in the research, development, and manufacturing of anesthesia and respiratory medical devices in China. In terms of global ecological layout, Beijing Aeonmed has not only established 28 provincial offices and 180 municipal offices across China, with business covering hospitals at all levels in all 31 provincial administrative regions of the country, but also set up subsidiaries in countries such as the United States, Germany, Mexico, Indonesia, India, South Africa, Uzbekistan, Russia, and the United Arab Emirates. Currently, more than 60 products have obtained EU CE certification, and its products are marketed in over 160 countries and regions worldwide.

Regarding this round of financing, Deng Yongru, Deputy General Manager of Beijing Aeonmed Co., Ltd., stated"In recent years, brain function protection has become a clinical focus in the field of anesthesiology and intensive care units. As a company incubated by a renowned domestic and international brain science team, Casibrain Technology possesses an inherent advantage in fundamental brain science research. At the same time, it is dedicated to the development of innovative devices for clinical scenarios. With its non-invasive cerebral oxygen monitor, the company quickly transformed it into a highly competitive product and successfully entered the European hospital market. As a leading enterprise in the large-scale research, development, and manufacturing of anesthesia and respiratory medical equipment, Beijing Aeonmed Co., Ltd. will support the scaled promotion of Casibrain Technology’s products, accelerating their expansion from 1 to 100. Additionally, leveraging our years of experience in innovative product development, we will help Casibrain Technology promote more of its innovative products both domestically and internationally."